Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$10.25 - $19.5 $78,925 - $150,150
7,700 Added 163.83%
12,400 $224,000
Q2 2024

Aug 14, 2024

SELL
$8.97 - $12.05 $38,571 - $51,815
-4,300 Reduced 47.78%
4,700 $48,000
Q1 2024

May 15, 2024

BUY
$6.21 - $11.05 $13,662 - $24,310
2,200 Added 32.35%
9,000 $95,000
Q4 2023

Feb 14, 2024

BUY
$6.99 - $10.71 $27,960 - $42,840
4,000 Added 142.86%
6,800 $62,000
Q3 2023

Nov 14, 2023

SELL
$10.26 - $15.7 $25,650 - $39,250
-2,500 Reduced 47.17%
2,800 $29,000
Q2 2023

Aug 14, 2023

BUY
$7.28 - $14.32 $24,752 - $48,688
3,400 Added 178.95%
5,300 $75,000
Q1 2023

May 15, 2023

SELL
$6.19 - $12.36 $53,234 - $106,296
-8,600 Reduced 81.9%
1,900 $13,000
Q4 2022

Feb 14, 2023

BUY
$9.18 - $11.53 $96,390 - $121,065
10,500 New
10,500 $117,000

Others Institutions Holding PHAT

About Phathom Pharmaceuticals, Inc.


  • Ticker PHAT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,175,200
  • Market Cap $351M
  • Description
  • Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...
More about PHAT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.